Oncolytic virus/drug combination therapy in breast cancer
This project looks to examine the efficacy and immunogenicity of combining agents used currently in the treatment of breast cancer, in particular small molecule inhibitors and immune checkpoint inhibitors, with oncolytic viruses, to enhance activation of an anti-tumour immune response.
Priming T cell responses against tumour-associated antigens in breast cancer
This project focuses on studying the activation of human anti-tumour T cell responses, focusing on characterising and testing the immunogenicity of specific breast cancer target proteins and peptides in human naïve and recall T cell priming assays. It looks to elucidate in detail the functional T cell responses and TCR repertoire of primed cytotoxic T cells, with a view to developing novel anti-cancer therapeutic vaccination strategies.